{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:31:35Z","timestamp":1788503495575,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22374073"],"award-info":[{"award-number":["22374073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011400","name":"State Key Laboratory of Analytical Chemistry for Life Science","doi-asserted-by":"publisher","award":["5431ZZXM2204"],"award-info":[{"award-number":["5431ZZXM2204"]}],"id":[{"id":"10.13039\/501100011400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011400","name":"State Key Laboratory of Analytical Chemistry for Life Science","doi-asserted-by":"publisher","award":["5431ZZXM2307"],"award-info":[{"award-number":["5431ZZXM2307"]}],"id":[{"id":"10.13039\/501100011400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113679","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T09:44:34Z","timestamp":1743673474000},"page":"113679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["DNA scaffold-framed natural killer cell with programmed drug release for chemo-adoptive cell therapy"],"prefix":"10.1016","volume":"382","author":[{"given":"Shiyi","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangxian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2025.113679_bb0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","article-title":"Engineering the next generation of cell-based therapeutics","volume":"21","author":"Bashor","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113679_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113679_bb0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-cell-transfer therapy for the treatment of patients with cancer","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113679_bb0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113679_bb0025","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.jconrel.2025.113679_bb0030","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113679_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","article-title":"Nanomaterials for T-cell cancer immunotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0040","doi-asserted-by":"crossref","first-page":"eabg4328","DOI":"10.1126\/scitranslmed.abg4328","article-title":"Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113679_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121506","article-title":"Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma","volume":"284","author":"Cheng","year":"2022","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113679_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Noninvasive detection of therapeutic cytolytic T cells with 18F\u2013FHBG PET in a patient with glioma","volume":"6","author":"Yaghoubi","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113679_bb0055","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and Management of on-target Toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.jconrel.2025.113679_bb0060","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113679_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with Ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.jconrel.2025.113679_bb0070","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical Cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113679_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113679_bb0080","doi-asserted-by":"crossref","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species\u2013responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113679_bb0085","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jconrel.2022.03.050","article-title":"In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma","volume":"345","author":"Wang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113679_bb0090","doi-asserted-by":"crossref","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0100","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/1097-0142(19890201)63:3<604::AID-CNCR2820630334>3.0.CO;2-2","article-title":"Side effects and emotional distress during cancer chemotherapy","volume":"63","author":"Love","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.113679_bb0105","doi-asserted-by":"crossref","first-page":"3e15","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0110","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113679_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01230-6","article-title":"Cell\u2013drug conjugates","author":"Wang","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113679_bb0120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nnano.2017.54","article-title":"Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence","volume":"12","author":"Xue","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113679_bb0125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41565-023-01374-7","article-title":"Neutrophil hitchhiking for drug delivery to the bone marrow","volume":"18","author":"Luo","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113679_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113679_bb0135","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nm.2198","article-title":"Therapeutic cell engineering with surface-conjugated synthetic nanoparticles","volume":"16","author":"Stephan","year":"2010","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113679_bb0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.jconrel.2025.113679_bb0145","doi-asserted-by":"crossref","first-page":"1900903","DOI":"10.1002\/smll.201900903","article-title":"Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy","volume":"15","author":"Yang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.113679_bb0150","article-title":"Cell-based drug delivery systems participate in the Cancer immunity cycle for improved Cancer immunotherapy","volume":"281","author":"Luo","year":"2022","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113679_bb0155","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nchem.1090","article-title":"Exploring and exploiting chemistry at the cell surface","volume":"3","author":"Mager","year":"2011","journal-title":"Nat. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113679_bb0160","doi-asserted-by":"crossref","first-page":"1804191","DOI":"10.1002\/smll.201804191","article-title":"Neoadjuvant chemotherapy based on Abraxane\/human neutrophils Cytopharmaceuticals with radiotherapy for gastric Cancer","volume":"15","author":"Ju","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.113679_bb0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2020.11.039","article-title":"A \u201cdual-guide\u201d bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence","volume":"329","author":"Qiu","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113679_bb0170","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1038\/s41467-021-24564-0","article-title":"Engineered macrophages as near- infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113679_bb0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2021.05.018","article-title":"Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: improved pharmacokinetics, cell internalization and anticancer efficacy","volume":"335","author":"Hussain","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113679_bb0180","doi-asserted-by":"crossref","first-page":"12096","DOI":"10.1021\/acsnano.8b05292","article-title":"Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth","volume":"12","author":"Deng","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113679_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri1603","article-title":"A new self: MHC-class-I-independent natural-killer-cell self-tolerance","volume":"5","author":"Kumar","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0190","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nri1863","article-title":"Self-tolerance of natural killer cells","volume":"6","author":"Raulet","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113679_bb0200","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.4049\/jimmunol.172.4.2048","article-title":"IL-21 induces the functional maturation of murine NK cells","volume":"172","author":"Jason","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.113679_bb0205","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.1021\/ja0459936","article-title":"Raman imaging of Plga microsphere degradation inside macrophages","volume":"126","author":"van Apeldoorn","year":"2004","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113679_bb0210","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113679_bb0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast Cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113679_bb0220","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","article-title":"T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors","volume":"24","author":"Hu","year":"2018","journal-title":"Clinical Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113679_bb0225","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113679_bb0230","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113679_bb0235","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0022-3565(24)39265-1","article-title":"Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1)","volume":"293","author":"Loe","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"17","key":"10.1016\/j.jconrel.2025.113679_bb0240","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1016\/j.bmc.2010.07.031","article-title":"Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1","volume":"18","author":"Barattin","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"35","key":"10.1016\/j.jconrel.2025.113679_bb0245","doi-asserted-by":"crossref","first-page":"1906783","DOI":"10.1002\/adma.201906783","article-title":"Realizing Cancer precision medicine by integrating systems biology and nanomaterial engineering","volume":"32","author":"Joo","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113679_bb0250","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/75022","article-title":"Active movement of T cells away from a chemokine","volume":"6","author":"Poznansky","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113679_bb0255","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/0008-5472.CAN-04-0143","article-title":"Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1","volume":"64","author":"Trompier","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113679_bb0260","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrc3339","article-title":"Aiding and abetting roles of NOX oxidases in cellular transformation","volume":"12","author":"Block","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113679_bb0265","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.jconrel.2025.113679_bb0270","doi-asserted-by":"crossref","first-page":"2202603","DOI":"10.1002\/adfm.202202603","article-title":"In situ activated NK cell as bio-orthogonal targeted live-cell Nanocarrier augmented solid tumor immunotherapy","volume":"32","author":"Meng","year":"2022","journal-title":"Adv. Funct. Mater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:57:00Z","timestamp":1777870620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925002998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"alternative-id":["S0168365925002998"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113679","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA scaffold-framed natural killer cell with programmed drug release for chemo-adoptive cell therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113679"}}